Skip to content

Home
Studies
Study Group
Publications
News

För allmänheten

BrainWise
Delta i våra studier

Stable episodic memory and high education do not influence the rate of Alzheimer’s disease pathology as measured by plasma p-tau217.

2026

bioRxiv [Preprint]. 2026 Apr 21:2026.04.16.718397. doi: 10.64898/2026.04.16.718397.PMID: 42079294

Avelar-Pereira B, Spotorno N, Orduña Dolado A, Bali D, Adolfsson AN, Mattsson-Carlgren N, Palmqvist S, Janelidze S, Hansson O, Nyberg L.

bioRxiv [Preprint]. 2026 Apr 21:2026.04.16.718397. doi: 10.64898/2026.04.16.718397.PMID: 42079294

2026 Plasma proteome profiling identified biomarkers for the differential diagnosis and molecular staging of neurodegenerative dementias.
2026 Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease: An Individual Participant Data Meta-Analysis.
2026 Multicenter validation of plasma p-tau217/ amyloid beta 1-42 ratio in symptomatic Alzheimer’s disease.
2026 Plasma eMTBR-tau243 and %p-tau217 for Biological Staging of Alzheimer Disease
2026 Provider and patient perspectives on the diagnosis and treatment of Alzheimer’s disease: A global perspective from the Global Alzheimer’s Leadership Series (GoALS).
2026 Plasma phosphorylated tau217 discordance with amyloid status in an ethnically diverse mixed memory clinic cohort.
2026 The Role of Clinical, Plasma, and Imaging Biomarkers in Assessing Future Dementia Risk in Individuals With Subjective Cognitive Decline
2026 Turning as a single and dual task-associations with Alzheimer’s and vascular pathologies in cognitively healthy older people.
2026 Multi-cohort proteogenomic analyses reveal genetic effects across the proteome and diseasome.
2026 Tau-PET and CSF MTBR-tau243 comparisons validate increased tau aggregation in females.
2026 Speech-based digital cognitive assessment for clinical trials: Detecting cognitive impairment stages and AD biomarker relations across European cohorts.
2026 Proteomic signatures of the APOE ε4 and APOE ε2 genetic variants and Alzheimer’s disease
2026 Generating synthetic tau-PET scans in Alzheimer’s disease from MRI, blood biomarkers and demographics with deep learning.
2026 Clinical staging in Swedish primary care using the Amsterdam Instrumental Activities of Daily Living Questionnaire.
2026 Comparability of Centiloid values from [18F]flutemetamol scans using seven commercial and research software

Follow us

Search for: